Rockwell Medical (NASDAQ:RMTI) issued its quarterly earnings results on Tuesday. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.01), MarketWatch Earnings reports. Rockwell Medical had a negative net margin of 47.23% and a negative return on equity of 117.67%.
NASDAQ:RMTI remained flat at $$1.16 on Thursday. The company’s stock had a trading volume of 1,720,803 shares, compared to its average volume of 2,151,846. Rockwell Medical has a 12-month low of $0.83 and a 12-month high of $2.62. The company has a market cap of $108.54 million, a price-to-earnings ratio of -2.70 and a beta of 1.11. The firm has a 50 day moving average of $1.42 and a two-hundred day moving average of $1.18. The company has a debt-to-equity ratio of 0.50, a current ratio of 6.13 and a quick ratio of 5.83.
Several equities research analysts have recently commented on the company. HC Wainwright cut their price objective on Rockwell Medical from $9.00 to $5.50 and set a “buy” rating for the company in a report on Monday, February 8th. Zacks Investment Research downgraded shares of Rockwell Medical from a “hold” rating to a “strong sell” rating in a research report on Friday, February 12th.
Rockwell Medical, Inc operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis. The company offers Triferic, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores; and Calcitriol, an active vitamin D injection for the management of hypocalcemia in patients undergoing chronic hemodialysis.
Featured Story: Return on Investment (ROI)
Receive News & Ratings for Rockwell Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical and related companies with MarketBeat.com's FREE daily email newsletter.